{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:58:38Z","timestamp":1792047518918,"version":"4.4.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Gene addition and editing strategies for transfusion-dependent \u03b2-thalassemia have gained momentum as potentially curative treatment options, with studies showcasing their efficacy and safety. We report, to our knowledge, the first real-world application of betibeglogene autotemcel (beti-cel; Zynteglo) during its period of active license in Europe from January 2020 to March 2022 for patients aged \u226512 years without a \u03b20\/\u03b20 genotype and without a HLA-matched sibling donor, before beti-cel marketing authorization was withdrawn by its holder because of nonsafety reasons. Among 15 screened patients, 4 opted out for fertility and safety concerns, 2 were excluded because of marked hepatic siderosis, and 1 had apheresis collection failure. Eight patients received beti-cel after busulfan myeloablative conditioning, all achieving transfusion independence within 8 to 59\u00a0days, with posttreatment hemoglobin levels ranging from 11.3 to 19.3 g\/dL. No deaths occurred, but acute toxicity mirrored busulfan\u2019s known effects. Posttreatment platelet management faced challenges because of HLA-antibodies in 3 patients. Monitoring up to month 24 revealed pituitary-gonadal endocrine dysfunction in all 3 female and in 2 of 5 male patients. Additionally, we observed unexpected posttreatment sequelae: 1 patient developed polycythemia that could not be explained by known genetic or acquired mechanisms, 1 patient developed posttreatment depression and anxiety prohibiting her from returning to work, and 1 patient developed fatigue severely compromising both quality of life and work capacity. This real-world experience corroborates beti-cel\u2019s efficacy and safety and provides information on adverse events observed during real-world use of the therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014104","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:44:36Z","timestamp":1729179876000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Gene therapy in transfusion-dependent non-\u03b20\/\u03b20 genotype \u03b2-thalassemia: first real-world experience of beti-cel"],"prefix":"10.1182","volume":"9","author":[{"given":"Adil","family":"Mirza","sequence":"first","affiliation":[{"name":"1Department of Pediatric Oncology, Hematology and Immunology and Hopp Children\u2019s Cancer Center, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Lisa","family":"Ritsert","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Hematology and Immunology and Hopp Children\u2019s Cancer Center, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tao","sequence":"additional","affiliation":[{"name":"2bluebird bio, Inc, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Thakar","sequence":"additional","affiliation":[{"name":"2bluebird bio, Inc, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Lobitz","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology and Oncology, Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heine","sequence":"additional","affiliation":[{"name":"4Pediatric Oncology and Hematology, Children's Hospital Medical Center, University Clinics Homburg, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Koscher","sequence":"additional","affiliation":[{"name":"5Pediatric Oncology, Hospital of the Goethe University Frankfurt Centre for Pediatrics and Adolescent Medicine, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-7740","authenticated-orcid":false,"given":"Matthias","family":"D\u00fcrken","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Oncology, University of Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Pavel","sequence":"additional","affiliation":[{"name":"8Stem Cell Laboratory, Institute of Clinical Transfusion Medicine and Cell Therapy Heidelberg GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Laier","sequence":"additional","affiliation":[{"name":"8Stem Cell Laboratory, Institute of Clinical Transfusion Medicine and Cell Therapy Heidelberg GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donate","family":"Jakoby","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Hematology and Immunology and Hopp Children\u2019s Cancer Center, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Greil","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Hematology and Immunology and Hopp Children\u2019s Cancer Center, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kunz","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Hematology and Immunology and Hopp Children\u2019s Cancer Center, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1953-0848","authenticated-orcid":false,"given":"Andreas","family":"Kulozik","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Hematology and Immunology and Hopp Children\u2019s Cancer Center, Heidelberg University Hospital, Heidelberg, Germany"},{"name":"9Clinical Cooperation Unit Pediatric Leukemia, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"issue":"8","key":"2025011415264490200_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025011415264490200_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/asheducation-2005.1.31","article-title":"Pathophysiology of beta thalassemia--a guide to molecular therapies","volume":"2005","author":"Thein","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2025011415264490200_bib3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/03007990802160834","article-title":"Costs, quality of life, treatment satisfaction and compliance in patients with \u03b2-thalassemia major undergoing iron chelation therapy: the ITHACA study","volume":"24","author":"Scalone","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2025011415264490200_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajh.21896","article-title":"Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms","volume":"86","author":"Sobota","year":"2011","journal-title":"Am J Hematol"},{"issue":"8","key":"2025011415264490200_bib5","first-page":"2165","article-title":"Anxiety, depression and quality of life in patients with beta thalassemia major and their caregivers","volume":"7","author":"Yengil","year":"2014","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"2025011415264490200_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.blre.2007.10.001","article-title":"Advances in the allogeneic transplantation for thalassemia","volume":"22","author":"Lucarelli","year":"2008","journal-title":"Blood Rev"},{"issue":"4","key":"2025011415264490200_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2025011415264490200_bib8","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/bloodadvances.2019000291","article-title":"Related and unrelated donor transplantation for \u03b2-thalassemia major: results of an international survey","volume":"3","author":"Li","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2025011415264490200_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/hematology.2022000326","article-title":"Hematology 2022--what is complete HLA match in 2022?","volume":"2022","author":"Spellman","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2025011415264490200_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"2025011415264490200_bib11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025011415264490200_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2020.01.002","article-title":"Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen","volume":"26","author":"Anurathapan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025011415264490200_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/03630269.2022.2059671","article-title":"Haploidentical hematopoietic stem cell transplantation in thalassemia","volume":"46","author":"Anurathapan","year":"2022","journal-title":"Hemoglobin"},{"issue":"5","key":"2025011415264490200_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non\u2013\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2025011415264490200_bib15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025011415264490200_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1566523214666141127095336","article-title":"Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease","volume":"15","author":"Negre","year":"2015","journal-title":"Curr Gene Ther"},{"issue":"1","key":"2025011415264490200_bib17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1196\/annals.1345.007","article-title":"A phase I\/II clinical trial of beta-globin gene therapy for beta-thalassemia","volume":"1054","author":"Bank","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"5550","key":"2025011415264490200_bib18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"issue":"16","key":"2025011415264490200_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025011415264490200_bib20","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1182\/blood-2022-162400","article-title":"Long term outcomes of 63 patients with transfusion-dependent \u03b2-thalassemia (TDT) followed up to 8 years post-treatment with betibeglogene autotemcel (beti-cel) gene therapy and exploratory analysis of predictors of successful treatment outcomes in phase 3 trials","volume":"140","author":"Walters","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025011415264490200_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2025011415264490200_bib22","doi-asserted-by":"crossref","unstructured":"Business wire\n          . Bluebird bio announces temporary suspension on phase 1\/2 and phase 3 studies of LentiGlobin gene therapy for sickle cell disease (bb1111). 2021. Accessed 27 June 2024. https:\/\/www.businesswire.com\/news\/home\/20210216005442\/en\/bluebird-bio-Announces-Temporary-Suspension-on-Phase-12-and-Phase-3-Studies-of-LentiGlobin-Gene-Therapy-for-Sickle-Cell-Disease-bb1111.","DOI":"10.1016\/S2666-6367(21)00039-7"},{"key":"2025011415264490200_bib23","unstructured":"Business Wire\n          . Bluebird bio announces positive recommendation by PRAC regarding article 20 safety referral review of ZYNTEGLO\u2122 gene therapy for transfusion-dependent \u03b2-thalassemia and marketing to resume in EU. 2021. Accessed 28 June 2024. https:\/\/www.businesswire.com\/news\/home\/20210709005202\/en\/."},{"issue":"3","key":"2025011415264490200_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.12631","article-title":"Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia major","volume":"164","author":"Klaassen","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2025011415264490200_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/trf.13951","article-title":"Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with \u03b2-thalassemia major","volume":"57","author":"Constantinou","year":"2017","journal-title":"Transfusion"},{"issue":"2","key":"2025011415264490200_bib26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.transci.2015.09.001","article-title":"Spontaneous splenic rupture following stem cell mobilization with G-CSF and plerixafor in AL amyloidosis","volume":"54","author":"Lessi","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"2025011415264490200_bib27","unstructured":"Zynteglo (betibeglogene autotemcel)\n          . Summary of product characteristics. 2022. Accessed 31 October 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zynteglo-epar-product-information_en.pdf."},{"issue":"9","key":"2025011415264490200_bib28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/ajh.22102","article-title":"Changing patterns of splenectomy in transfusion-dependent thalassemia patients","volume":"86","author":"Piga","year":"2011","journal-title":"Am J Hematol"},{"issue":"7","key":"2025011415264490200_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2020.03.016","article-title":"Matched family versus alternative donor hematopoietic stem cell transplantation for patients with thalassemia major: experience from a tertiary referral center in South India","volume":"26","author":"Swaminathan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025011415264490200_bib30","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbmt.2018.01.023","article-title":"Unrelated donor transplantation in children with thalassemia using reduced-intensity conditioning: the URTH trial","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2025011415264490200_bib31","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2019-126046","article-title":"Northstar-2: updated safety and efficacy analysis of Lentiglobin gene therapy in patients with transfusion-dependent \u03b2-thalassemia and non-\u03b20\/\u03b20 genotypes","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025011415264490200_bib32","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1182\/blood-2022-157601","article-title":"Clinical and economic outcomes in patients with transfusion-dependent \u03b2-thalassemia and patients with sickle cell\u00a0disease with recurrent Vaso-occlusive crises receiving hematopoietic stem cell transplants in the United States","volume":"140","author":"Udeze","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025011415264490200_bib33","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.bbmt.2014.07.016","article-title":"Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification","volume":"20","author":"Anurathapan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2025011415264490200_bib34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2020.06.004","article-title":"Reduced toxicity conditioning for nonmalignant hematopoietic cell transplants","volume":"26","author":"Contreras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2025011415264490200_bib35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bbmt.2015.05.017","article-title":"Single daily busulfan dosing for infants with nonmalignant diseases undergoing reduced-intensity conditioning for allogeneic hematopoietic progenitor cell transplantation","volume":"21","author":"Ward","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2025011415264490200_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1702695","article-title":"Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120\u00a0mg\/kg)","volume":"26","author":"Grigg","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2025011415264490200_bib37","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41409-019-0639-5","article-title":"The impact of low dose busulfan on gonodal function after allogeneic hematopoietic stem cell transplantation for aplastic anemia","volume":"55","author":"Kerbauy","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2025011415264490200_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s13312-021-2258-7","article-title":"Pubertal development and its determinants in adolescents with transfusion-dependent thalassemia","volume":"58","author":"Singh","year":"2021","journal-title":"Indian Pediatr"},{"issue":"6","key":"2025011415264490200_bib39","first-page":"e15572","article-title":"Investigating the role of ferritin in determining sexual underdevelopment in beta-thalassemia major patients: a cross-sectional analysis from Pakistan","volume":"13","author":"Shahid","year":"2021","journal-title":"Cureus"},{"key":"2025011415264490200_bib40","doi-asserted-by":"crossref","first-page":"617204","DOI":"10.1155\/2013\/617204","article-title":"Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress","volume":"2013","author":"Roussou","year":"2013","journal-title":"Anemia"},{"issue":"1","key":"2025011415264490200_bib41","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"key":"2025011415264490200_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2021.01.003","article-title":"Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells","volume":"95","author":"Russkamp","year":"2021","journal-title":"Exp Hematol"},{"issue":"suppl 1","key":"2025011415264490200_bib43","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2023-174068","article-title":"Sustained efficacy, safety, and improved quality of life in adult and pediatric patients with transfusion-dependent \u03b2-thalassemia up to 9 years post treatment with betibeglogene autotemcel (beti-cel)","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025011415264490200_bib44","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1891\/1061-3749.25.3.E202","article-title":"Psychometric evaluation of the Persian translation of the thalassemia-specific quality of life questionnaire","volume":"25","author":"Adib-Hajbaghery","year":"2017","journal-title":"J\u00a0Nurs Meas"},{"issue":"2","key":"2025011415264490200_bib45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40271-020-00473-0","article-title":"Patient- and caregiver-reported burden of transfusion-dependent \u03b2-thalassemia measured using a digital application","volume":"14","author":"Paramore","year":"2021","journal-title":"Patient"},{"issue":"5-6","key":"2025011415264490200_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/03630269.2018.1553183","article-title":"Quality of life of Pakistani children with \u03b2-thalassemia major","volume":"42","author":"Yasmeen","year":"2018","journal-title":"Hemoglobin"},{"issue":"10","key":"2025011415264490200_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.bmt.1705624","article-title":"Experience of severe fatigue in long-term survivors of stem cell transplantation","volume":"39","author":"Gielissen","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025011415264490200_bib48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/NCC.0000000000000405","article-title":"Persistent fatigue in hematopoietic stem cell transplantation survivors","volume":"40","author":"Hacker","year":"2017","journal-title":"Cancer Nurs"},{"issue":"8","key":"2025011415264490200_bib49","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.29877","article-title":"Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation","volume":"122","author":"Jim","year":"2016","journal-title":"Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/29\/2349572\/blooda_adv-2024-014104-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/29\/2349572\/blooda_adv-2024-014104-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T10:51:17Z","timestamp":1736851877000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/29\/518216\/Gene-therapy-in-transfusion-dependent-non-0-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014104","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}